Literature DB >> 19666153

The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection.

J Carcelén1, V Iniesta, J Fernández-Cotrina, F Serrano, J C Parejo, I Corraliza, A Gallardo-Soler, F Marañón, M Soto, C Alonso, C Gómez-Nieto.   

Abstract

The protective potential against Leishmania infection of the Leishmania chimerical Q protein administered as a single (Q) or double dose (Q+Q) without adjuvant was analyzed in a double-blind placebo controlled experiment in dogs. During vaccination the protein induced an intense early anti-Q response but no reactivity against total Leishmania infantum proteins was detected. Several end-points were taken into consideration. In the vaccinated animals the amount and intensity of clinical symptoms was lower than in the control group. Pathological signs of disease were observed in liver, kidney and spleen of all dogs from the control group in contrast to the normal appearance of the organs of the vaccinated animals. Vaccination was able to induce parasite clearance in most dogs. Only 1/7 dog was parasite DNA positive in skin in the Q group in contrast to 6/7 dogs in control and 4/7 in Q+Q. Significant anti-SLA clearance was observed in the vaccinated animals at the end of the study. Differences between control and vaccinated animals were also observed at the biochemical level, DTH and nitrite oxide production.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19666153     DOI: 10.1016/j.vaccine.2009.07.069

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts.

Authors:  Eduardo A F Coelho; Laura Ramírez; Mariana A F Costa; Vinicio T S Coelho; Vivian T Martins; Miguel A Chávez-Fumagalli; Dulcilene M Oliveira; Carlos A P Tavares; Pedro Bonay; Carlos Gómez Nieto; Daniel R Abánades; Carlos Alonso; Manuel Soto
Journal:  Clin Vaccine Immunol       Date:  2009-10-07

2.  LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.

Authors:  Rodrigo Dian de Oliveira Aguiar-Soares; Bruno Mendes Roatt; Henrique Gama Ker; Nádia das Dores Moreira; Fernando Augusto Siqueira Mathias; Jamille Mirelle de Oliveira Cardoso; Nelder Figueiredo Gontijo; Oscar Bruna-Romero; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho; Rodrigo Corrêa-Oliveira; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  Parasit Vectors       Date:  2014-02-07       Impact factor: 3.876

3.  Characterisation of the ex vivo virulence of Leishmania infantum isolates from Phlebotomus perniciosus from an outbreak of human leishmaniosis in Madrid, Spain.

Authors:  Gustavo Domínguez-Bernal; Maribel Jiménez; Ricardo Molina; Lara Ordóñez-Gutiérrez; Abel Martínez-Rodrigo; Alicia Mas; Maria Teresa Cutuli; Javier Carrión
Journal:  Parasit Vectors       Date:  2014-11-07       Impact factor: 3.876

4.  Vaccination with Leishmania infantum acidic ribosomal P0 but not with nucleosomal histones proteins controls Leishmania infantum infection in hamsters.

Authors:  Lais Pereira; Melissa Abbehusen; Clarissa Teixeira; Jurema Cunha; Ivan P Nascimento; Kyioshi Fukutani; Washington dos-Santos; Aldina Barral; Camila Indiani de Oliveira; Manoel Barral-Netto; Manoel Soto; Cláudia Ida Brodskyn
Journal:  PLoS Negl Trop Dis       Date:  2015-02-02

Review 5.  Vaccines for canine leishmaniasis.

Authors:  Faeze Foroughi-Parvar; Gholamreza Hatam
Journal:  Adv Prev Med       Date:  2014-12-31

6.  Immunogenicity and Efficacy of Live L. tarentolae Expressing KMP11-NTGP96-GFP Fusion as a Vaccine Candidate against Experimental Visceral Leishmaniasis Caused by L. infantum.

Authors:  Vahid Nasiri; Abdolhossein Dalimi; Fatemeh Ghaffarifar; Azam Bolhassani
Journal:  Iran J Parasitol       Date:  2016 Apr-Jun       Impact factor: 1.012

7.  F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.

Authors:  Eugenia Carrillo; Laura Fernandez; Ana Victoria Ibarra-Meneses; Micheli L B Santos; Dirlei Nico; Paula M de Luca; Cristiane Bani Correa; Roque Pacheco de Almeida; Javier Moreno; Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2017-07-12       Impact factor: 7.561

8.  Performance of LBSap vaccine after intradermal challenge with L. infantum and saliva of Lu. longipalpis: immunogenicity and parasitological evaluation.

Authors:  Bruno Mendes Roatt; Rodrigo Dian de Oliveira Aguiar-Soares; Juliana Vitoriano-Souza; Wendel Coura-Vital; Samuel Leôncio Braga; Rodrigo Corrêa-Oliveira; Olindo Assis Martins-Filho; Andréa Teixeira-Carvalho; Marta de Lana; Nelder Figueiredo Gontijo; Marcos José Marques; Rodolfo Cordeiro Giunchetti; Alexandre Barbosa Reis
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

9.  Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease.

Authors:  Carmen Pineda; Escolastico Aguilera-Tejero; Maria C Morales; Silvia Belinchon-Lorenzo; Luis C Gomez-Nieto; Pablo Garcia; Julio M Martinez-Moreno; Maria E Rodriguez-Ortiz; Ignacio Lopez
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

10.  NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.

Authors:  Dirlei Nico; Fernanda Martins Almeida; Juliana Maria Motta; Fellipe Soares Dos Santos Cardoso; Celio Geraldo Freire-de-Lima; Leonardo Freire-de-Lima; Paula Melo de Luca; Ana Maria Blanco Martinez; Alexandre Morrot; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.